Stockpolly
Search
Delisting risk
PPCB · NASDAQ · Biotechnology

Propanc Biopharma (PPCB)

Preclinical developer of proenzyme therapies for solid tumors.

$1.04
Pre-market+0.02 (+1.46%)
At close$1.03(−9.29%)
Watchlist

In millions of USD, except per-share figures

In millionsQ4 FY23Jun 2023Q1 FY24Sep 2023Q2 FY24Dec 2023Q3 FY24Mar 2024Q4 FY24Jun 2024Q1 FY25Sep 2024Q2 FY25Dec 2024Q3 FY25Mar 2025Q4 FY25Jun 2025Q1 FY26Sep 2025Q2 FY26Dec 2025Q3 FY26Mar 2026
Cost of revenue0000—0000000
Gross profit0000—0000000
0000000534546
Research & development000000000000
0000000534546
General & administrative0000000534546
Operating income0000000−53−4−5−4−6
−1000000−10010
Interest income000000000000
Interest expense000000000000
Other non-operating income0000000100−10
Income before tax−10−1−1000−54−4−5−3−6
Income tax expense000000000000
Net income from continuing operations−10−1−1000−54−4−5−3−6
Net income−10−1−1000−54−4−5−3−6
EPS, basic−$3.25−$1.12−$25,704.75−$7,419.25−$2,398.75−$7,195.50−$805.50−$312.50−$8.75−$9.75−$7.50−$7.00
EPS, diluted−$3.25−$1.12−$25,704.75−$7,419.25−$2,398.75−$7,195.50−$805.50−$312.50−$8.75−$9.75−$7.50−$7.00
Weighted average shares, basic00—————00——1
Weighted average shares, diluted00—————0———1
EBITDA−1000000−54−4−5−3−6
Depreciation & amortization000——0000000
EBIT−1000000−54−4−5−3−6